PR Newswire, Tuesday, 10 December 1996.

According to a written summary of the trial by Dr. Levett, forty-three patients never previously treated with HIV anti-retroviral therapy, were enrolled in the study. Twenty-one patients received RETICULOSE and twenty-two patients received placebo, administered daily, every other week, for a sixty- day period. Patients were observed for another sixty days following the conclusion of treatment.

The polymerase chain reaction (PCR) assays for viral load were performed by LabCorp (Roche), and the CD4 counts were performed by SmithKline Beecham Clinical Laboratories.

At the end of the sixty-day treatment period, the key results of this preliminary report were:

-- A 37 percent increase in the mean CD4 positive T-cell lymphocytes counts in patients receiving RETICULOSE as compared with a 7 percent decrease in the control group that received placebo, and

-- A 21 percent average decrease in HIV viral load, as measured by quantitative RNA PCR, in the RETICULOSE-treated patients, in contrast to a 33 percent increase in HIV viral load in the control group.

At the end of the sixty-day observation period the mean HIV viral load of the treated group was less than half (42 percent) of the control group.

Eighty-three percent of the patients who received RETICULOSE had a rise in blood hemoglobin and 61 percent had a rise in hemoglobin equal to or greater than one gram per deciliter (gm/dl). In contrast, 44 percent of patients who received placebo had a rise in blood hemoglobin during the study period, and in only 25 percent was the increase equal to or greater than 1 gm/dl.

Clinically, 72 percent of patients who were given RETICULOSE maintained or increased their body weight. This occurred in only 30 percent of the placebo- treated patients.

There was zero toxicity and no side effects were observed by physicians or reported by patients as a result of RETICULOSE therapy.

"In view of the encouraging preliminary results of this clinical study in AIDS patients and the absence of any toxic side effects, we are eager to move forward to the next stage of this clinical trial with RETICULOSE," said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral Research Corp. "Drs. Fraser, Roach and Levett plan to submit the results for publication upon completion of the trial."

The study is being supported by Advanced Viral Research Corp. ADVR is developing RETICULOSE, a non-toxic peptide nucleic acid preparation, that in the past was used to treat a number of viral infections. The company has neither monitored nor observed this clinical trial.

NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. RETICULOSE is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. SOURCE Advanced Viral Research Corp

961210
PR961222

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .